MycoBiomDB – Record Details (MyCo_3229)

Biomarker Record Details

Database ID: MyCo_3229
DB IDMyCo_3229
TitlePrognostic value of serial (1,3)-β-D-glucan measurements in ICU patients with invasive candidiasis
Year2024
PMID38997712
Fungal Diseases involvedInvasive candidiasis
Associated Medical ConditionICU patients
GenusCandida
Speciesparapsilosis
OrganismCandida parapsilosis
Ethical StatementThe study received approval from the local ethic committee (UCSC1123/11); patients’ informed consent was waived due to the observational design.
Site of InfectionNone
Opportunistic invasiveInvasive
Sample typeBody fluid
Sample sourceSerum
Host GroupHuman
Host Common nameHuman
Host Scientific nameHomo sapiens
Biomarker NameBDG
Biomarker Full Name1-3-beta-D-Glucan
Biomarker TypePrognostic
BiomoleculeProtein
Geographical LocationItaly
CohortIn the study population of 103 patients (age 47 [35–62] years, SAPS II score 67 [52–77]) 68 bloodstream and 35 intrabdominal infections were recorded.
Cohort No.103
Age Group35–62
P ValueNone
SensitivityNone
Specificity1
Positive Predictive Value1
MICNone
Fold ChangeNone
PathwayNone
Disease Introduction MechanismInvasive candidiasis (IC) remains the most common seri- ous fungal infection in intensive care unit (ICU) patients and it is still associated with high mortality rates. Prompt diagnosis and appropriate therapy are of upmost importance in this setting; however, in almost half cases blood/tissue cultures could result negative and the iden- tification of pathogens as well as their antifungal suscep- tibility definition could take some days.
TechniqueELISA
Analysis MethodFDA Approved-Fungitell assay
ELISA kitsNone
Assay DataFDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA
Validation Techniques usedFDA Approved-Fungitell assay
Up Regulation Down RegulationDecrease
Sequence DataNone
External LinkNone